TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 1 of 46 INVESTIGATIONAL PLAN/PROTOCOL 
 
The Portable Organ Care System (OCS™) Heart  For R esuscitation, Preservation and Assessment of 
Hearts from Donors after C irculatory Death Continued Access Protocol ( OCS DCD Heart CAP ) 
 
 
 
 
Number OCS -CAR -0824 2020  
 
 
Sponsor:  TransMedics, Inc.  
200 Minuteman Road, Suite 302  
Andover, MA 01810  
Sponsor Primary Contact:   
 
m 
Sponsor Secondary Contact:   
 
 
 
  
CONFIDENTIAL – PROPRIETARY INFORMATION  
 
Protocol Rev  Issue Date  
1.0 16-September -2020 
   

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 2 of 46 TABLE OF CONTENTS  
OCS DCD HEART CAP SY NOPSIS  ............................................................................................................ 5  
1. INTRODUCTION AND BAC KGROUND INFORMATI ON .................................................................... 8  
1.1. Heart Transplantation and Current Clinical Challenges  ........................................................... 8  
2. SUMMARY OF PRIOR TES TING AND INVESTIGATIONS  ................................................................. 13 
2.1. OCS Heart Preclinical Testing  ................................................................................................. 13 
2.2. Preclinical Animal Testing of OCS Heart System for DCD hear ts ........................................... 13 
2.2.1.  Iyer, et al., 2015  ................................................................................................................ 13 
2.2.2.  García Sáez, et al., 2015  .................................................................................................... 14 
2.3. OCS Heart Clinical Testing for DCD Hearts Outside the U.S.  .................................................. 15 
2.3.1.  Messer, et al., 2017  .......................................................................................................... 15 
2.3.2.  Dhital, et al. (2015 and 2017)  ........................................................................................... 16 
2.3.3.  García Sáez, et al. (2016, 2017)  ........................................................................................ 17 
2.3.4.  Chew, et al. (2019)  ............................................................................................................ 17 
2.4. Additional Clinical Studies of the OCS Heart System for Standard and Extended Criteria 
and DCD Donor Hearts ........................................................................................................... 18 
2.5. Overall Summary of Clinical Data to Support OCS DCD Heart CAP  ........................................ 20 
3. DEVICE DESCRIPTION  .................................................................................................................. 20 
3.1. Description of Major Components  ......................................................................................... 20 
3.1.1.  OCS Heart Console  ............................................................................................................ 20 
3.1.2.  Heart Perfusion Set (HPS)  ................................................................................................. 21 
3.1.3.  OCS Heart Solution Set  ..................................................................................................... 21 
3.1.4.  Mode of Action - Overview  .............................................................................................. 22 
4. TRIAL OBJECTIVES  ....................................................................................................................... 23 
4.1. Trial Design  ............................................................................................................................. 23 
4.2. Trial Size and Subject Follow -up ............................................................................................. 23 
5. TRIAL ENDPOINTS ....................................................................................................................... 23 
5.1. Primary E ndpoint  .................................................................................................................... 23 
5.2. Secondary Endpoint  ............................................................................................................... 23 
5.3. Safety Endpoint  ...................................................................................................................... 23 
5.4. Other E ndpoints  ..................................................................................................................... 23 
6. TRIAL POPULATION  .................................................................................................................... 24 
6.1. DCD Donor Eligibility Criteria  ................................................................................................. 24 
6.2. Recipient Eligibility Criteria  .................................................................................................... 24 
6.3. DCD Heart Subject Enrollment and Screen Failures  ............................................................... 25 
7. PRE-OPERATIVE TRIAL PROCEDURES  .......................................................................................... 26 
7.1. Subject Identification  ............................................................................................................. 26 
7.2. Recipient Day of Transplant Assessment  ............................................................................... 26 
7.3. Donor Screening and Acceptance for DCD Hearts  ................................................................. 26 
7.4. DCD Donor Heart Retrieval and OCS Preservation and Assessment  ..................................... 26 
7.4.1.  Donor Heart Acceptance/Rejection for Transplantation after OCS Preservation  ............ 26 
8. TRANSPLANT, IMMEDIATE POST -OPERATIVE AND  LONG -TERM FOLLOW -UP .............................. 27 
8.1. Transplant Details  ................................................................................................................... 27 
8.2. Post -transplant Functional Assessments Day 0 – Day 30 ....................................................... 27 
8.3. Long-term Follow -up: 6 and 12 Months  ................................................................................ 28 
8.4. Evaluation of Adverse Events ................................................................................................. 28 
8.4.1.  Serious Adverse Events (SAEs) .......................................................................................... 28 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 3 of 46 8.4.2.  Heart Graft- Related SAEs (HGRSAEs)  ............................................................................... 28 
8.4.3.  Unanticipated Adverse Device Effect (UADE) ................................................................... 28 
8.4.4.  Anticipated SAEs  ............................................................................................................... 29 
8.4.5.  Reporting of Adverse Events  ............................................................................................ 30 
8.4.6.  Relationship of an SAE or HGRSAE to OCS Heart System  ................................................. 30 
8.4.7.  Severity  ............................................................................................................................. 30 
8.4.8.  Pre-Existin g Conditions  ..................................................................................................... 30 
9. OCS HEART TRAINING R UNS  ....................................................................................................... 31 
10. STATISTICAL METHODS  ............................................................................................................... 31 
10.1.  Gene ral ................................................................................................................................... 31 
10.2.  Analysis Populations  ............................................................................................................... 31 
10.2.1.  DCD Heart Transplanted Recipient Population  ................................................................ 31 
10.2.2.  OCS Heart Population  ....................................................................................................... 31 
10.2.3.  Modified Intend -to-Treat (mITT) Population  .................................................................... 31 
10.3.  Statistical Analysis  .................................................................................................................. 31 
10.3.1.  Primary Endpoint  .............................................................................................................. 31 
10.3.2.  Secondary and Other Endpoints  ....................................................................................... 32 
10.4.  Safety ...................................................................................................................................... 32 
10.5.  Sample Size Determination .................................................................................................... 32 
11. RISK ANALYSIS  ............................................................................................................................ 32 
11.1.  Potential Risks  ........................................................................................................................ 33 
11.2.  Manner in Which the Potential Risks Have Been Minimized  ................................................. 33 
11.3.  Potential Benefits  ................................................................................................................... 34 
11.4.  Risks Benefit Ratio  .................................................................................................................. 34 
12. DEVICE/SITE MANAGEME NT ....................................................................................................... 34 
12.1.  Packaging and Labeling  .......................................................................................................... 34 
12.2.  Storage  ................................................................................................................................... 34 
12.3.  Accountability  ......................................................................................................................... 35 
12.4.  Device Complaints and Malfunctions  ..................................................................................... 35 
13. REGULATORY/ETHICS  ................................................................................................................. 35 
13.1.  Institutional Review Boards (IRB)  ........................................................................................... 35 
13.2.  Informed Consent ................................................................................................................... 35 
14. DATA COLLECTION/RECORDS/REPORTS ...................................................................................... 35 
14.1.  Investigator Records  ............................................................................................................... 35 
14.2.  Investigator Reports  ............................................................................................................... 36 
14.3.  Data Collection  ....................................................................................................................... 37 
14.4.  Source Documents  ................................................................................................................. 37 
14.5.  Archiving of Records  ............................................................................................................... 37 
15. CLINICAL MONITORING  .............................................................................................................. 37 
15.1.  Monitoring  .............................................................................................................................. 37 
15.2.  Site Initiation Visit  .................................................................................................................. 38 
15.3.  Periodic Monitoring Visits  ...................................................................................................... 38 
15.4.  Frequency of Monitoring Visits  .............................................................................................. 39 
15.5.  Study Close-out Visit  .............................................................................................................. 39 
15.6.  Protocol Deviations  ................................................................................................................ 39 
15.7.  Clinical Events Committee (CEC)  ............................................................................................ 39 
15.8.  Data Safety Monitoring Board & Stopping Rules  ................................................................... 39 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 4 of 46 15.9.  Investigator Training  .............................................................................................................. 40 
16. CONFIDENTIALITY  ....................................................................................................................... 40 
17. AMENDMENT POLICY  ................................................................................................................. 40 
18. REFERENCES  ............................................................................................................................... 41 
APPENDIX 1:  ISHLT  CONSENSUS MANUSCRIP T HEART PRIMARY GRAFT DYSFUNCTION (PGD) 
(KOBASHIGAWA, ET AL., 2014)  ....................................................................................... 43 
APPENDIX 2:  SCHEDULE OF CLINICAL ASSESS MENTS ......................................................................... 44 
APPENDIX 3:  DRAFT PATIENT INFORMED CONS ENT FORM TEMPLATE  .............................................. 45 
APPENDIX 4:  DRAFT ELECTRONIC CASE REPOR T FORMS  .................................................................... 46 
 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 5 of 46   OCS DCD HEART CAP SYNOPSIS 
Protocol Title  The Portable Organ Care System (OCS™) Heart for Resuscitating, Preserving and Assessing Hearts Donated 
after Circulatory Death Continued Access Protocol (OCS DCD Heart CAP) 
Objectives  To enable continued clinical access to DCD heart transplantation in the U .S. and to continue to collect 
additional data on the performance of t he OCS Heart System to resuscitate, preserve and assess hearts 
donated after circulatory death for transplantation to increase the pool of donor hearts available for 
transplantation .  
Trial Design  A prospective , single arm , continu ed access protocol . 
 Trial Size  A maximum of 25 participating sites transplanting up to 90 DCD heart recipients .  
Screening and 
Treatment  Donor DCD hearts that may  be a cceptable for transplant will be screened for trial eligibility. Eligible DCD 
donor hearts will be preserved and assessed with the Organ Care System (OCS). After OCS preservation 
and assessment, DCD donor hearts will be evaluated for acceptability for transplantation according to 
prespecified criteria.  
 
Primary heart transplant candidates will be screened for trial eligibility. Eligible heart transplant candidates 
will receive OCS preserved DCD donor hearts that have been deemed clinically acceptable for 
transplantation following preservation by the treating transplant clinical team according to specified 
criteria.  
DCD  Donor Heart 
Eligibility Criteria  Inclusion  
• Maastricht Category III DCD donor, defined as expected death after the withdrawal of life - 
supportive therapy (WLST)  
• Donor age 18 -49 years old inclusive  
• Warm ischemic time (WIT) ≤  30 mins, with warm ischemic time defined a s: Time from when mean 
systolic blood pressure ( SBP) is < 50 mmHg or peripheral saturation <  70% to aortic cross -clamp 
and administration of cold cardioplegia  in the donor . 
 Exclusion 
• Previous cardiac surgery ; 
• Known coronary artery disease ; 
• Cardiogenic shock or myocardial infarction ; 
• Sustained terminal EF of ≤  50% ; or 
• Significant valve disease except for competent bicuspid aortic valve . 
Recipient  
Eligibility Criteria  Inclusion  
• Primary heart transplant candidates  
• Age ≥  18 years old  
• Signed: (1) written informed consent document ; (2) authorization to use and disclose protected 
health information ; and ( 3) consent to TransMedics’ use of recipients’ UNOS/OPTN data  and 
recipients’ INTERMACS data . 
Exclusion 
• Prior solid organ or bone marrow transplant 
• Chronic use of hemodialysis or diagnosis of chronic renal insufficiency  
• Multi -organ transplant . 
DCD Donor Heart on 
OCS Transplant 
Criteria  Accept for Transplantation  
Donor hearts preserved on the OCS Heart System to be maintained within the following target ranges : 
• Stable or downward trending lactate after i nitial adjustments of the OCS Heart perfusion 
parame ters to achieve adequate perfusion to the donor heart 
• Stability of OCS Heart perfusion parameters within range:  
o AOP 40 -100 mmHg  
• Transplanting surgeon and/or heart failure cardiologist must clinically accept the OCS perfused 
donor heart for transplant. 
Reject for Transplantation  
• Transplanting surgeon and/or heart failure cardiologist clinically unsatisfied with donor heart 
condition/performance on the OCS Heart System at final evaluation  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 6 of 46 • Unstable and rising arterial lactate despite maneuvers to optimize perfusion p arameters . 
 
Note: Certain donor hearts may require perfusion with parameters outside of these guidance ranges. 
Acceptance for transplantation should be primarily based on an acceptable lactate trend.  
Primary Endpoint  • Patient survival at 6 months post -transplant . 
Secondary Endpoint  • Utilization Rate, defined as the number of eligible DCD donor hearts that met the warm ischemic time 
limit above and were instrumented on the OCS Heart System that meet the acceptance criteria for 
transplantation after  OCS Heart preservation divided by the total number of eligible DCD donor hearts 
that met the warm ischemic time limit above and were instrumented on the OCS Heart System.  
Other Endpoints  • Patient and graft survival at 30  days post -transplant  
• Patient and  graft survival at 30  days or initial hospital discharge, if later than 30  days  
• Severe heart primary graft dysfunction (PGD) (left or right ventricle) (not including rejection or cardiac 
tamponade) according to ISHLT consensus manuscript (as defined in  Appendix 1  of this protocol)  
• Use of post- transplant mechanical circulatory support (LVAD, RVAD, BiVAD) for >  72 hours  
immediately post -transplant. 
• Patient survival at 1 year after transplant . 
Safety Endpoint  The safety endpoint is d efined as the incidence of heart graft -related Serious Adverse Events (HGRSAEs) in 
the first 30 days post -heart transplantation in the DCD Heart Transplanted Recipient Population , defined as  
the following adverse events (at most one per type) : 
• Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac 
tamponade) according to ISHLT consensus manuscript (as defined in  Appendix 1  of this protocol) . 
• Primary graft failure requiring retransplantation . 
Follo w-up • All patients will be followed for 12 months  in the study database; then through 5  year s via the 
UNOS/OPTN database.  
Statistical Methods  The DCD Heart Transplanted Recipient Population  will consist of all eligible recipients who are 
transplanted with an eligible DCD donor heart that met the warm ischemic time limit defined above, 
preserved on OCS and met the transplantability criteria. The analyses of all effectiveness and safety 
endpoi nts, except the utilization rate, will be based on the DCD Heart Transplanted Recipient Population.  
 
The OCS Heart Population  will consist of all eligible donor hearts that met the warm ischemic time limit 
above and were instrumented on the OCS Heart Syste m. The analysis of utilization rate will be based on 
the OCS Heart population.  
 
The modified intend -to-treat (mITT) population  will consist of all recipients who are transplanted 
according to this protocol. The mITT analysis will be considered secondary analyses of all effectiveness and 
safety endpoints except the rate of donor heart utilization.  
 
The primary endpoint will be summarized using counts and percentages and an exact 95% confidence 
interval for the true percentage based on the binomial distributi on. 
 
Each other  endpoint will be summarized using counts and percentages and an exact (Clopper -Pearson) 
95% confidence interval for the true percentage based on the binomial distribution.  
 
The rate of donor hearts that were successfully transplanted after preservation and assessment on the OCS 
Heart System (i.e., donor heart utilization)  will be summarized using counts and percentages and an exact 
95% confidence interval for the true percentage based on the binomial distribution.  
 
Serious Adverse Events (SA Es) and Heart Graft- related Serious Adverse Events (HGRSAEs) will be collected 
within the first 30 days post -transplant and the mean number of HGRSAEs per subject will be summarized 
using descriptive statistics. HGRSAEs are defined as the following adverse  events (at most one per type): 
Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) 
according to ISHLT consensus manuscript (as defined in Appendix 1  of this protocol) and primary gr aft 
failure requiring retransplantation.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 7 of 46 SAEs and HGRSAEs will also be tabulated using counts and percentages alone and in regards to the 
relationship of the HGRSAE to the device, and the severity of the HGRSAE.  
Determination of 
Sample Size  This is a continued access protocol and does not have a statistically determined sample size . 
Trial Sponsor  TransMedics, Inc.  
200 Minuteman Road, Suite 302  
Andover, MA, USA 01810  
 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 8 of 46 1. INTRODUCTION AND BACKGROUND INFORMATION  
The OCS DCD Heart Continued Access Protocol (CAP) is a continuation of the OCS DCD Heart  trial 
which recently completed enrollment.  The purpose of the OCS DCD Heart CAP  is to enable continued 
clinical access to DCD heart transplantation in the U .S. and to continue to collect additional data on 
the performance of the OCS Heart  System while patient foll ow-up is completed and the marketing 
application for the OCS Heart  System for DCD donor hearts is prepared and undergoes review at the 
FDA.  
1.1. Heart  Transplantation and Current Clinical Challenges  
Heart transplantation is the gold standard and the most cost- effective treatment for end- stage heart 
failure (Hunt and Haddad 2008). While the demand for heart transplantation globally has increased 
significantly each year, the utilization or recovery of availab le donor hearts for transplantation has 
been limited. Based on the Organ Procurement and Transplantation Network (OPTN) 2014 report, 4,323 (approximately 50%) consented, donor hearts in the U .S. are not recovered annually, depriving 
thousands of patients the gift of new hearts to treat their end- stage heart disease  (Israni, et al. , 2016) 
(see Figure  1). 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 9 of 46 Figure 1: Heart Organ Use in the U.S. in 2014 (Figure DOD7.5 from OPTN/SRTR Annual Data Report 
2014) (Isra ni, et al. , 2016) 
 
 
The donor organ shortage has also led to an increasing utilization of Mechanical Circulatory Support 
(MCS) devices, which are being used as  either a “Bridge to Transplant” or as a replacement for organ 
transplantation (“Destination Therapy”)  (Figure  2). 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 10 of 46 Figure 2: MCS devices implanted in U .S. patients, 2006-September 2017. From INTERMACS Quarterly 
Statistical Report, 2017. (Kirklin, et al. , 2017)  
 
 
MCS devices are being implanted in patients who are candidates for heart transplant (so -called Bridge 
to Transplant (BTT) indication) solely as a result of the donor organ shortage.  The American Heart 
Association, ISHLT, The American Transplant Society and investigators in the U .S. and worldwide 
recognize heart transplant as the  “gold standard” treatment and the only curative therapy for end 
stage heart failure. (Peura, et al., 2012; Katz, et al., 2015; Wilhelm, 2015 ; Mancini, 2010 ; 
Kobashigawa, et al., 2017).  In fact, this shortage of donor organs results in approximately 16% of the 
Status 1A patients listed on the national waiting list for heart transplantation dying or deteriorating 
so much that they were removed from the waiting list at 12 months ( Table  1). Status 1A patients 
include those who were implanted with MCS devices while awaiting transplant.  
  

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 12 of 46 Figure 3: DCD Donors and DBD Donors in the U.S.  
 
However, due to potential damage of warm ischemia in the donor and the functional arrest of the 
heart that may never recover, DCD donors are not utilized for adult heart transplantation in the U .S. 
In contrast, international transplant centers have been successfully transplanting hearts from DCD donors, using the OCS Heart System for resuscitation, preservation and assessment of these hearts prior to transplantation. The OCS Heart System can minimize the detrimental effects of ischemia because it perfuses the donor heart with warm oxygenated blood. It enables the heart to be 
resuscitated to full beating state, and importantly enables the transplant team to assess metabolic 
(lactate production) and perfusion parameters of these hearts to determine their suitability for transplantation. These capabilities are critical when using extended criteria and DCD donor hearts to minimize the risks on the recipients receiving these organs.  
Currently, the TransMedics’ OCS Heart technology is the only portable system available for ex -vivo 
maintenance of the donor heart in a metabolically active and beating state.  
Specifically, with regard to the challenges posed by DCD donor hearts noted above, the OCS Heart 
System offers the following advantages and capabilities:  
• Resuscita tion of the  DCD heart into beating physiologic state ex -vivo to enable for the 
assessment of the donor heart’s viability . 
• Reduction of the time -dependent ischemic injury to the donor hearts during preservation, 
thus eliminating significant logistical and geographical barriers to heart transplantation that currently exist with cold storage preservation.  
• Optimization of donor heart ex -vivo environment by optimizing oxygen and substrate 
delivery, while also replenishing key hormones and nutrients that are depleted due to the brain -dead condition in the body of the donor , which  would negatively impact cardiac 
function if not replenished.  
• Assessing the adequacy of the perfusion and metabolic condition of the donor heart 
utilizing standard lactate levels to allow physicians to judge the suitability of the organ for 
transplantation using the standard criteria that physicians currently use when harvesting 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 13 of 46 the organ from the donor, thus substantially minimizing the risk of transplanting poor 
hearts into recipients.  
In summary, patients listed for heart transplantation due to their end stage heart disease are 
suffering from a terminal, life -threatening condition. Increasing the number of heart transplants by 
preserving extended criteria donors  and DCD hearts  with the OC S Heart System has the potential to 
provide patients with end stage heart failure with the gold- standard, life -saving treatment.  
2. SUMMARY OF PRIOR TES TING AND INVESTIGATI ONS  
2.1. OCS Heart  Preclinical Testing  
The OCS Heart  System is CE marked and has undergone extensive preclinical testing to demonstrate 
its safety, effectiveness, and readiness for clinical use.  The Heart  Perfusion Set has also been 
evaluated and tested in accordance with ISO -10993 “Biological Evaluation of Medical Devices,” 
including evaluations for acute toxicity, irritation, sensitization, cytotoxicity, hemolysis, genotoxicity and pyrogenicity.  These test results demonstrated that the device and its materials are biocompatible 
and suitable for their intended use.  The Heart  Perfusion Set will be provided sterile using validated 
methods, and is appropriately packaged to maintain sterility.  The OCS has also undergone extensive 
preclinical bench testing for: electrical safety ; electromagnetic compatibility ; and validation and 
verification testing ( including validation of the device software).  All tests and results have 
demonstrated that the OCS meets its expected performance specifications and is safe and suitable for clinical use.  
2.2. Preclinical Animal Testing of OCS Heart System for DCD hearts  
Two pr eclinical animal studies have been published that evaluated the use of the OCS Heart System 
to preserve DCD hearts in animal models.  
2.2.1.  Iyer, et al., 2015  
This study evaluated the use of the OCS Heart System to preserve DCD hearts in a porcine orthotopic hear t transplant model. DCD hearts preserved with the OCS Heart System were compared to DCD 
hearts preserved using standard cold storage for 4 hours.  
All donor hearts were exposed to 30 minutes of warm ischemia in a DCD asphyxia model prior to being flushed wi th cardioplegia.  The comparison of the experimental timeline for the two groups is 
shown in Figure  4 below. Orthotopic transplantation into recipient animals was then performed.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 14 of 46 Figure 4: Comparison of Experimental Timeline for OCS and Control G roups (Figure 1 from Iyer, et al. , 
2015)  
 
Five of six hearts preserved with the OCS heart system demonstrated favorable lactate profiles and all 
five could be weaned off cardiopulmonary bypass post- transplant compared to 0 of 3 hearts 
preserved with cold storage.  The authors concluded that DCD hearts preserved with the OCS heart 
system demonstrated viability before and after transplant, and that human studies of DCD hearts using the OCS Heart System are warranted.  
2.2.2.  García Sáez , et al., 2015  
This study evaluated the use of the OCS Heart System to preserve DCD hearts in an ex vivo porcine model.  
Circulatory death was induced in  five pigs and the agonal time was calculated as the time between a reduction 
in blood pressure < 50 mm Hg or a fall in saturation below 70% and the cessation of electrical activity.  After an 
additional 15 minutes of warm ischemia, hearts were procured and  instrumented on the OCS and the procured 
grafts were assessed over a period of 4 hours. The results showed that four hearts were successfully 
resuscitated on the system with agonal times of 8, 15, 20 and 34 minutes. These grafts had good visual 
contractil ity and declining lactate and were considered transplantable. One graft, with agonal time = 34 
minutes, had increased lactate and abnormal contractility and was not considered suitable for transplant. One 
heart with 48 minutes of agonal time could not be r esuscitated.  The authors compared the hemodynamic 
parameters during OCS perfusion and degree of edema after explantation with historical control grafts and no 
significant difference was found (Table  2). 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 15 of 46 Table  2: Comparison of H emodynamic  Parameters for DCD Hearts Preserved on OCS and Historical 
Control (standard criteria hearts) preserved on OCS (Table 1 from García Sáez, et al., 2015)  
 
The authors concluded that the hearts from DCD donors can be successfully resuscitated on the OCS 
in a scenario that simulates clinical conditions.  
2.3. OCS Heart Clinical Testing for DCD Hearts Outside the U .S. 
Due to the damage done by warm ischemia and the mechanical arrest in the donor, only DBD donors are currently utilized for adult heart transplantation in the U.S. In contrast, international transplant centers have been transplanting hearts from DCD donors, using the OCS Heart System for resuscitation, preservation and assessment of these hearts prior to transplantation. The OCS Heart 
System can minimize the detrimental effects of ischemia because it perfuses the donor heart with 
warm oxygenated blood. It enables the heart to be resuscitated to full beating state, and importantly enables the transplant team to assess metabolic (lactate production) and perfusion parameters of these hearts to determine if their suitability for transplantation. These capabilities are critical when using marginal/questionable and DCD donor hearts to minimize the risks on the recipients receiving these organs.  
2.3.1.  Messer , et al., 2017  
Messer , et al. (2017) has published the results of a study of the OCS Heart System for preserving DCD 
donor hearts in the UK. This was a single -center observational matched cohort study comparing 
consecutive patients who received transplants of DCD donor hearts between February 1, 2015, and March 31, 2017, vs . matched recipients who received transplants of DBD donor hearts between 
February 1, 2013, and March 31, 2017. There was no difference in implant technique or immunosuppressive regimens during this period. DCD hearts were transported and continually perfused on the OCS Heart System. DBD hearts all underwent the current standard of direct procurement and cold storage until transplantation.  
DCD heart donors were restricted to Maastricht category III donors, defined as expected death after the withdrawal of life - supportive therapy (WLST). A retrospective cohort of DBD heart transplants, 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 16 of 46 matched for donor and recipient characteristics, was used as a comparison group. The primary 
outcome measure of this study was 90-day survival. There were 26 DCD heart transplants performed 
during the 25 -month study period. The use of the OCS Heart System resulted in an 86.7% rate of 
successful utilization of DCD hearts for transplantation. Survival at 90 days was not significantl y 
different between DCD and matched DBD transplant recipients (DCD, 92%; DBD, 96%; p=1.0).  
Hospital length of stay, treated rejection episodes, allograft function, and 1 -year survival (DCD, 86%; 
DBD, 88%; p=0.98) were comparable between groups.  
Of the 26 D CD hearts transplanted, 12 used Normothermic Regional Perfusion ( NRP) before OCS and 
14 used Direct Procurement and Preservation ( DPP). During the NRP procedure, following circulatory 
arrest the cerebral circulation was terminated but perfusion was restore d to the thoracic and 
abdominal organs within the donor body.  Functional assessments of the heart were performed after 
which donor blood was collected and the heart was arrested with cold cardioplegia.  (NRP will not be 
used in this study). The DPP procedure followed the standard OCS blood collection and cardioplegic arrest of the donor heart.  In the DPP arm, utilization was  77.8% (14/18) and 90- day survival was 86% 
(12/14).  
Figure 5: K-M S urvival of Recipients of DCD and DBD Donors (Figure 2 from Messer, et al. , 2017)  
 
The authors noted that DCD heart transplantation may increase heart transplants by 17% to 30%. During the study period, 84 DBD heart transplants were performed at this institution and the 2 6 
additio nal DCD heart transplants increased the number of transplants by 33%. The authors concluded 
that the adoption of DCD heart transplantation can be safely implemented into widespread routine clinical practice.  
2.3.2.  Dhital , et al. (2015 and 2017) 
The first report, published in 2015 in the Lancet, described transplantation of DCD hearts into three 
recipients (two men, one woman; mean age 52 years). They received Maastricht category III controlled hearts donated after circulatory death from people younger than 40 years and with a 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 17 of 46 maximum warm ischemic time of 30 min.  Donor heart warm ischemic times were 28 min, 25 min, and 
22 min, with O CS Heart perfusion times of 257 min, 260 min, and 245 min, respectively. Two patients 
needed temporary mechanical support. All three recipients had normal cardiac function within a 
week of transplantation, and, at the time of the report, were alive and recovering well at 176, 91, and 77 days after transplantation.  
The second report, published in 2017, described the experience of using the OCS Heart System to 
preserve DCD hearts at St. Vincent’s Hospital in Sydney, Australia. The donors were Maastricht Category III donors, < 40 years of age, no history of cardiac disease or cardiac risk factors, minimal 
inotropes and an expected warm ischemia time of 30 minutes. All donor hearts were perfused with the OCS Heart System. Time from withdrawal of therapy to cessation of circulation was  4 to 25 
minutes (median 14 minutes). Total warm ischemic time was 14 to 28 minutes (median 25 minutes), with the time on OCS from 210 to 410 minutes (mean 302 minutes).  Results for 12 patients have been 
reported. One patient needed mechanical support with IABP and 4 patients required ECMO support. There has been no mortality and all patients have normal biventric ular function at 25 to 829 days 
post -transplant at the time of the report.  The authors concluded that excellent graft and recipient 
survival can be achieved from transplantation with DCD hearts using the OCS Heart System . 
2.3.3.  García  Sáez, et al. (2016, 2017)  
García Sáez, et al. (2016) reported on the outcomes of 2 recipients with long -term left ventricular 
assist device (LVAD) support who were successfully transplanted with DCD hearts preserved on the 
OCS Heart System despite the adverse donor/recipient risk profile. The authors noted “The ability to 
assess graft viability is of particular importance in DCD HTx, where, in contrast to the DBD setting, the donor organ has invariably been subjected to a sustained ischemic insult before procurement. We deliberately prolonged OCS support duration to allow comprehensive graft assessment and to 
achieve surgical preparedness in technically demanding recipients with LVADs in situ.” In this report, the two patients were alive and well 290 and 291 days after transplantation. 
This same author followed up with a report of 5 high- risk recipients ( García Sáez, et al., 2017). This 
included three recipients with LVADs and one subject who was undergoing a second heart 
transplantation. All patients received DCD heart transplants preserved on OCS. Following transplant, two patients developed primary graft dysfunction requiring mechanical support. One patient died within the first 30  days post -transplant (the patient who had undergone a second heart transplant). 
The remaining 4 patients are well and alive at a mean 324 days post -transplant (range 18 -496 days). 
2.3.4.  Chew, et al . (2019) 
Chew , et al . reported on experience of 23 DCD heart transplants from 45 DCD donor referrals that 
were transplanted between July 2014 and April 2018 at St. Vincent’s Hospital, Sydney, Australia.  
Hearts were retrieved from 33 of 45 DCD donors. A total of 12 donors did not progress to circulatory 
arrest within the pre -speciﬁed timeframe. Eight (8) hearts failed to meet viability criteria during 
normothermic machine perfusion, and 2 hearts were declined due to machine malfunction, leading to 23  DCD heart transplants. A ll recipients had successful implantation, with mechanical circulatory 
support utilized in 9 cases. One case requiring extracorporeal membrane oxygenation subsequently died on the sixth post- operative day, representing a mortality of 4.4% over 4 years with a total follow -
up period of 15,500 days for the entire cohort. All surviving recipients had normal cardiac function on 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 18 of 46 echo cardiogram and no evidence of acute rejection on discharge. All surviving patients remain in New 
York Heart Association functional class I with normal biventricular function.  
Figure 6: Recipient Survival after DCD and DBD Heart Tra nsplantation (Chew, et al., 2019) 
 
2.4. Additional Clinical Studies of the OCS Heart System for Standard and Extended Criteria 
and DCD  Donor Hearts  
TransMedics has conducted two previous IDE studies of the OCS Heart System in Standard Criteria 
and Extended Criteria Donor Heart s, and one IDE study is currently ongoing using the OCS Heart 
System for DCD Donor Hearts . These studies provide supporting evidence for the safety of the OCS 
Heart System for this investigation  and are briefly described below.  
• The OCS Heart EXPAND trial was a prospective, single arm study of 75 heart transplant 
recipients who received hearts preserved on the OCS. These hearts were from extended criteria donors, i.e., those that are seldom transplanted in transplant institutions today witho ut the OCS.  The results demonstrated : 
− Utilization rate of 80.6% of donor hearts that are rarely used for transplantation today. These donor hearts were refused by other (non- EXPAND) centers an average of 6 6 
times but were able to be preserved and 8 1% were transplanted successfully in this 
study. 
− The incidence of ISHLT severe PGD was 10.7%, and the incidence of ISHLT moderate or severe PGD was 14.7%. These rates compare favorably with contemporary literature 
reporting PGD rates post- heart transplantation using the ISHLT criteria.  
− Survival at 30 days , 6 months , and 12 months was 9 5%, 88% , and 84% , respectively.  

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 19 of 46 • The FDA also approved a Continued Access Protocol (CAP) for EXPAND called the EXPAND 
CAP. The study is on- going and data are still being collected, but  based on the available 
data the results show:  
− 45 donor hearts were preserved and assessed on the OCS Heart System.  
− The utilization rate is 91.1% , with 41 of 45 extended criteria donor hearts successfully 
transplanted. 
− The 41 transplanted patients have rea ched a minimum of 30 -day follow -up and all 
survived (100% survival at 30- days).  Twenty- six (26) patients have reached 6 months 
post -transplant and these patients experienced 100% graft and patient survival.  
− The incidence of ISHLT severe heart PGD was 2.1% , and the  incidence of ISHLT 
moderate or severe PGD was 17.1%  
• PROCEED II was the first pivotal study of the OCS Heart System. It was a randomized study of the OCS Heart System compared to standard of care cold storage, and it enrolled 
standard criteria don or hearts. The study met its primary endpoint and non- inferiority was 
shown in 30 -day survival, as well as in the secondary endpoint, i.e., cardiac graft -related 
SAEs. Longer -term data, obtained from the SRTR database, showed lower survival rates for 
the OCS group at 2 -3 years of follow -up; however, the incidence of cardiac graft- related 
deaths was similar and other deaths were typical for heart transplant recipients (late 
infection, malignancy, multi- organ failure). Th e results of this study were published in the 
Lancet (Ardehali, et al. , 2015) . 
• Studies of the OCS Heart System for preservation of standard criteria donor hearts conducted outside the U.S. at hospitals in Germany and the UK showed improved rates of 
survival and lower rates of PGD for OCS compared to standard of care cold storage 
(Koerner , et al. , 2014). 
• The OCS DCD Heart trial is an IDE trial that is currently being conducted by TransMedics in 
the U.S. In this trial 90 patients were to be transplanted with DCD hearts  preserved on the 
OCS H eart System  and up to 90 patients were to be transplanted with standard of care 
hearts that were preserved on cold storage.  The study is still ongoing; the patients are still 
being followed in the study and the 6 month primary endpoint data has not yet bee n 
analyzed. The OCS DCD Heart study data has been reviewed by an independent Data 
Safety Monitoring Board (DSMB) and no study concerns have been identified.  Preliminary 
and available data show: 
− 84 DCD donor hearts were preserved and assessed on the OCS Hea rt System.  
− The donor heart utilization rate  as defined in the study protocol  is 91.1%.  
− 43 transplanted patients have reached a minimum of 30 -day follow -up and all patients 
and grafts survived (100% survival at 30 -days).  
− The incidence of ISHLT defined severe heart PGD was  14%, and the incidence of 
HGRSAE (moderate or severe PGD ) was 16.3%. There have been no primary graft 
failures.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 20 of 46 2.5. Overall Summary of Clinical Data to Support OCS DCD Heart CAP 
In summary, studies of the OCS Heart System for the preservation of DCD hearts have been 
performed outside of the U .S. These studies have shown 77.8 - 86.7% utilization rate, with 90 -day and 
1-year survival comparable to outcomes obtained with standard criteria donor hearts preserved using 
cold storage standard of c are. TransMedics is currently conducting the OCS DCD Heart t rial. The 
preliminary data are encouraging and show a utilization rate of 9 1.1% and 30- day patient survival of 
100% in the 43 patients who have reached this follow-up. 
In addition, the OCS Heart EXPAND trial, the OCS Heart EXPAND CAP  and studies of the use of OCS to 
preserve extended criteria hearts performed outside the U .S. shows high utilization rate, with good 
clinical outcomes, demonstrating the ability of the OCS Heart System to expand the potential pool of donor organs. These data provide strong support for the OCS DCD Heart CAP. 
3. DEVICE DESCRIPTION  
The OCS Heart System is an integrated portable platform designed to maintain donor hearts in a near physiologic, normothermic  perfusion state. The OCS Heart System consists of:  
• OCS Heart Console  
• OCS Heart Perfusion Set – comprised of Heart Perfusion Module (HPM) and Accessories  
• OCS Heart Solution Set  
These major components are shown in Figure  7 below. 
Figure 7: Figures of the OCS Heart System  
 
3.1. Description of Major Components  
3.1.1.  OCS Heart Console  
The OCS Heart Console is the reusable, non -sterile  portable enclosure incorporating the electronics, 
software, fluid pumping systems, monitoring systems, power supply, batteries, gas cylinder, mobile 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 21 of 46 base and Wireless Monitor. The Wireless Monitor displays information and allows the user to adjust 
certain  settings.  
The OCS Heart Console provides a rigid compartment to house and securely connect to the HPM during transport. The OCS Heart Console connects to a mobile base with locking wheels.  
3.1.2.  Heart Perfusion Set (HPS)  
The Heart Perfusion Set (HPS) consists of the Heart Perfusion Module (HPM) and Disposable Accessories. The HPM provides a closed circulatory system to protect, maintain and support the heart. It uses a physical conduit to connect to the heart, incorporates various sensors, and interfaces with the OCS Heart Console to oxygenate, warm and circulate the perfusate.  
The accessories are intended to:  
• Collect and process the donor blood  
• Prime and then infuse the OCS Heart Solution to the HPM 
• Connect the heart to the HPM circuit  
• Facilitate monitoring of  the heart operation  
• Infuse cardioplegia to terminate the preservation . 
The HPM provides the sterile blood circuit and protected environment for a heart within the OCS. It is designed as a single -use, pre -assembled module that mounts into the OCS. The heart is instrumented 
within the heart chamber of the HPM. The Wireless Monitor displays measurements made within the HPM. The HPM includes:  
• Dual lid heart -specific heart chamber  
• Integrated and easily accessible blood sampling and de -airing manifold  
• Integr ated pulsatile pump head interface  
• Integrated low shear titanium blood warmer  
• Integrated blood oxygenator (or gas exchanger)  
• Integrated sensors (pressure and temperature) and circuitry to communicate with the Console . 
3.1.3.  OCS Heart Solution Set  
The OCS Heart S olution Set consists of two proprietary heart preservation solutions, a Priming 
Solution and a Maintenance Solution, to replenish the nutrients and hormones (adenosine) that the metabolically active donor heart requires. The solutions are packaged in a three- chamber bag 
(nominal volume of 500 ml per chamber). At the time of use, the Priming Solution (500 ml) is dispensed into the HPM. The Maintenance Solution is manufactured as two component solutions 
(500 ml each) that are individually manufactured and then mixed immediately before infusion into 
the HPM. Additives are required at the time of use. The additives are not supplied by TransMedics, and are added by user.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 22 of 46 The OCS Heart Solution Set is not intended to be administered directly to the donor or the re cipient. 
The donor heart is arrested prior to removal using a standard cardioplegia solution. Prior to 
transplantation into the recipient, the donor heart is arrested on the OCS through the use of a standard cardioplegia solution, at which time the perfusate (including the donor blood, Priming Solution and Maintenance Solution) are flushed from the donor heart.  
3.1.4.  Mode of Action - Overview  
The OCS Heart System preserves the heart in a near- physiological, beating state by perfusing the 
heart with a warmed, dono r-blood based perfusate that is supplemented with nutrients and oxygen 
in a controlled and protected environment referred to as the circuit. The circuit is illustrated in Figure  8 below . The OCS contains a pulsatile pump that directs flow through the gas exchanger, to be 
oxygenated, and then through the blood warmer and then to the aorta of the donor heart. An additional perfusate component, known as the TransMedics Maintenance Solution, is infused into 
this circuit. The heart consumes oxygen and nutrients as the blood travels from the aorta through the 
coronary arteries and returns blood to the circuit through its pulm onary artery. The OCS maintains 
the blood at a constant temperature, oxygenates the perfusate at a constant rate, and provides perfusate in a pulsatile flow at a constant rate.  
Figure 8: Schematic of the OCS Heart Sy stem Fluid Flow  
 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 23 of 46 4. TRIAL  OBJECTIVES  
The objective of the OCS DCD Heart CAP is to enable continued clinical access to DCD heart 
transplantation in the U .S. and to continue to collect additional data on the performance of the OCS 
Heart System to resuscitate, preserve and assess hearts donated after circulatory death for 
transplantation to increase the pool of donor hearts available for transplantation . 
4.1. Trial Design  
This is a  prospective, single arm, continued access protocol (CAP).  
4.2. Trial Size  and Subject Follow- up 
A maximum of 25 participating sites and up to 90 transplanted DCD heart recipients will participate . 
Subjects will be followed for 12  months from the date of transplantation (some of which may be 
post -market). Data from UNOS/OPTN transplantation database will be obtained through 5 years after 
transplant. The follow -up assessments are summarized in Appendix 2 . 
5. TRIAL  ENDPOINTS  
5.1. Primary Endpoint 
The primary endpoint is patient survival at 6 months post-transplant. 
5.2. Secondary Endpoint  
Utilization Rate  is defined as the number of eligible DCD donor hearts that met the warm ischemic 
time limit and were instrumented on the OCS Heart System that meet the acceptance criteria for 
transplantation after OCS Heart preservation divided by the total number of eligible DCD donor hearts that met the warm ischemic time limit above and were instrumented on the OCS Heart System.  
5.3. Safety Endpoint 
The safety endpoint is defined as the incidence of Heart G raft-related Serious Adverse Events 
(HGRS AEs) in the first 30 days post- heart transplantation  in the DCD Heart Transplanted Recipient 
Population , defined as  the following adverse events (at most one per type) : 
• Moderate or Severe heart  PGD (left or right ventricle) (not including rejection or cardiac 
tamponade) according to ISHLT consensus manuscript (as defined in Appendix 1
 of this 
protocol ). 
• Primary graft failure requiring retransplantation . 
5.4. Other Endpoints   
Other endpoints include:  
• Patient and graft survival at 30  days post -transplant 
• Patient and graft survival at 30  days or initial hospital discharge, if later than 30  days 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 24 of 46 • Severe PGD (left or right ventricle) (not including rejection or cardiac tamponade) 
according to ISHLT consensus manuscript (as defined in Appendix 1  of this protocol)  
• Use of post -transplant mechanical circulatory support (LVAD, RVAD, BiVAD) for >  72 hours  
immediately post -transplant . 
• Patient survival at 1 year after transplant . 
6. TRIAL  POPULATION  
The trial will include primary heart  transplant recipients . Medicare beneficiaries with a clinical need 
for transplantation will be treated in the same manner as patients not covered by a Medicare plan. The rules of participation and results of the study apply to Medicare and non- Medicare co vered 
patients in the same manner.  
6.1. DCD Donor Eligibility Criteria  
Donor Inclusion Criteria  
• Maastricht Category III DCD donor, defined as expected death after the withdrawal of life - 
supportive therapy (WLST)  
• Donor age 18- 49 years old  inclusive  
• Warm ischemic time (WIT) ≤ 3 0 mins , with wa rm ischemic time defined as:  Time from 
when mean systolic blood pressure ( SBP) is < 50 mmHg or peripheral saturation <  70% to 
aortic cross -clamp and administration of cold cardioplegia in the donor.  
Donor Exclusion Criteria  
Donor hearts will be excluded if they meet any of the following criteria:  
• Previous cardiac surgery ; 
• Known coronary artery disease ; 
• Cardiogenic shock or myocardial infarction ; 
• Sustained terminal EF of ≤  50% ; or 
• Significant valve disease except for competent bicuspid aortic valve . 
6.2. Recipient Eligibility Criteria  
Recipient Inclusion Criteria  
• Primary heart transplant candidates  
• Age ≥  18 years old  
• Signed: ( 1) written informed consent document; (2) authorization to use and disclose 
protected health information; and (3) consent to TransMedics’ use of recipients’ 
UNOS/OPTN data  and consent to TransMedics’ use of recipients’ INTERMACS data . 
Recipient Exclusion Criteria  
• Prior solid organ or bone marrow transplant  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 25 of 46 • Chronic use of hemodialysis or diagnosis of chronic renal insufficiency  
• Multi- organ transplant . 
6.3. DCD Heart Subject Enrollment  and Screen Failures  
As part of the screening process  for subjects in the OCS DCD CAP, the following must occur : 
• Recipient must be matched with a DCD donor heart that meets eligibility  criteria ; 
• Recipient must meet eligibility criteria; 
• The matched DCD donor heart must be accepted for transplantation in the donor chest by 
the transplant surgeon or designee  (including meeting the Warm Ischemic Time limit 
outlined in this protocol) ; 
• The matched donor heart must be instrumented on the OCS ; 
• The donor heart matched to this recipient must meet transplantability criteria per Section 
7.4.1 of the protocol following OCS Heart System instrumentation; and 
• The recipient must be transplanted with the DCD heart instrumented on OCS . 
 
A subject will be considered a screen failure under any of the following conditions:  
• The matched DCD donor heart is not accepted for transplantation in the donor chest by 
the transplant surgeon or designee (including meeti ng the Warm Ischemic Time limit 
outlined in this protocol) . 
• The matched DCD donor heart is not instrumented on the OCS . 
• The donor heart  matched to this recipient fails to meet transplantability criteria per 
Section  7.4.1 of the protocol following OCS Heart System i nstrumentation (i.e., donor 
heart turndown) . 
• The recipient fails to meet inclusion/exclusion criteria on the day of the potential transplant after a n eligible DCD donor heart is  instrumented on the OCS Heart  System  and 
accepted for transplantation following OCS  preservation . 
• Logistical reasons prevent transplantation of DCD donor heart instrumented on the OCS 
Heart  System  that meets acceptance criteria for transplant following OCS preservation  
(e.g. , transplant center or OPO issues, transportation  or allocation issues, surg eons or ORs 
are unavailable) . 
A subject will be considered enrolled  in the study when the subject is transplanted with the OCS -
instrumented organ. Trial data will be collected only for those subjects considered enrolled in the 
trial.  
Subjects who are scre en failures that remain eligible for the study will return to  the waiting list for 
another heart transplant.  Depending on the donor match, this next transplant may be either in the  
OCS DCD Heart CAP or the subject may be transplanted using standard cold storage and will not be  
enrolled in this study . 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 26 of 46 7. PRE-OPERATIVE TRIAL  PROCEDURES  
7.1. Subject Identification  
Those patients who initially appear eligible for the trial will have the trial explained to them, be 
invited to participate, and will be asked to sign an informed consent.  When a matching  eligible  DCD 
donor heart becomes available, the inclusion and exclusion criteria for the recipient will be re -
verified . If the recipient is no longer eligible for the trial, they will be considered a screen failure and 
they will exit the study, and no information will be collected  for these subjects.  
7.2. Recipient Day of Transplant Assessment  
The p urpose is to conduct a final assessment of whether the potential recipient still meets the 
eligibility criteria.  Specific data to be collected can be found in the Schedule of Assessments in 
Appendix 2 . 
7.3. Donor Screening and Acceptance  for DCD Hearts  
The investigator or a member of her/his transplant team will evaluate the donor and the quality and 
suitability of the DCD heart  for: (1) transplantation, according to his or her clinical judgement and (2)  
eligibility for the DCD Heart arm of this study , including meeting the warm ischemic time limit 
outlined in this protocol . If the donor heart does not meet the above criteria, it will be considered a 
“dry run” and no informat ion on this donor heart will be collected.  
If the donor heart meets the above criteria  and is preserved on OCS , baseline characteristics, 
demographics and other donor information will be collected at this visit. Parameters to be collected 
can be found in the Schedule of Assessments in Appendix 2 . 
7.4.  DCD Donor Heart  Retrieval and OCS Preservation and Assessment  
Upon acceptance into the trial, the investigators will retrieve and preserve the donor heart  according 
to the OCS Heart Instructions for Use (IFU).  
7.4.1.  Donor Heart  Acceptance/Rejection  for Transplantation after OCS Preservation  
Donor hearts preserved on the OCS should have stable parameters throughout perfusion after initial stabilization  period (defined as the time period during which perfusion is initiated and primary 
parameter adjustments are made ). 
Accept for Transplantation 
Donor hearts preserved on the OCS Heart System to be maintained within the following target 
ranges : 
• Stable or downward trending lactate after initial adjustments of the OCS Heart perfusion 
parameters to achieve adequate perfusion to the donor heart 
• Stability of OCS Heart Perfusion Parameters within range:  
− AOP 40 -100 mmHg . 
• Transplanting surgeon and/or heart failure cardiologist must clinically accept the  OCS 
perfused donor heart for transplantation. 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 27 of 46 Reject for Transplantation 
• Transplanting surgeon and/or heart failure cardiologist clinically unsatisfied with donor 
heart condition/performance on the OCS Heart System at final evaluation . 
• Unstable and rising  arterial lactate despite maneuvers to optimize perfusion parameters . 
Note: certain donor hearts may require perfusion with parameters outside of these guidance ranges.  
Acceptance for transplantation should be primarily based on an acceptable lactate trend . 
Any decision to turndown hearts after preservation and assessment on OCS Heart System should be 
documented on the appropriate CRF. The turndown heart should be sent to the central core lab for assessment of any inherent cardiac pathology that was not diagnosed at retrieval of the donor heart.  
8. TRANSPLANT, IMMEDIATE POST -OPERA TIVE AND LONG-T ERM FOLLOW -UP 
8.1. Transplant Details  
The following i nformation concerning the transplant procedure  will be collected : 
• The organ recipient unique post- transplant patient identifier 
• Warm ischemic time as defined in this protocol  
• Total cross clamp duration in minutes (from donor cross -clamp application to removal of 
cross -clamp in the recipient)  
• Pre-OCS cold ischemia time (time from donor cross clamp until start of perfusion  on OCS)  
• Post -OCS cold ischemia time (time from heart flush on OCS until aortic cross -clamp 
removal in the recipient)  
• Any surgical complications encountered during surgery . 
8.2. Post-t ransplant Functional Assessments Day 0 – Day 30  
• Heart PGD Surveillance  in the  first 2 4 hours 
• Initial use of Mechanical Circulatory Support  in the first 72 hours  
• Inotropic Support for first 24 hours  from T0 to T24 hours after ICU admission  
• Echocardiogram results within the first 24 hours  post -transplant (if available)  starting from 
ICU admission  
• Right Heart Catheter Data  (not required; data collected only if performed as part of 
institution’s standard of care)  
• Initial Post -Transplant ICU Stay  
• Initial Post -Transplant Hospital Stay  
• Patient and Graft Survival at Day 30  will be assessed . 
• Serious Adverse Events : All SAE s will be collected for the first 30 days post-transplant. SAEs 
will be followed until the investigator designates the event to be either resolved or its effect on the patient’s condition stabilized.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 28 of 46 8.3. Long -term Follow -up: 6 and 12 M onths  
Follow -up data collection will be conducted at 6 months (± 30 days) and 12 months (± 60 days) post -
transplant to evaluate patient survival, graft survival and diagnosis of cardiac  allograft vasculopathy. 
These follow -ups may be performed by phone . 
8.4. Evaluation of Adverse Events  
Only serious adverse events (SAEs) and Heart Graft- Related SAEs (HGRSAEs) will be captured in this 
study. 
8.4.1.  Serious Adverse Events (SAEs)  
Serious adverse events  will be collected only through Day 30 post -transplant. An adverse event will 
be classified as serious if it meets any of the following criteria:  
• Results in, leads to, or contributes to, a death 
• Is life -threatening 
• Results in permanent disability or incapacity (i.e., permanent impairment of a body 
function or permanent damage to a body structure)  
• Requires in -patient hospitalization or prolongs hospitalization  
• Necessitates medical or surgical intervention to preclude a permanent disability or incapacity  
• Resu lts in fetal distress, fetal death or a congenital anomaly/birth defect. 
8.4.2.  Heart Graft- Related SAEs  (HGRSAEs)  
Heart Graft -related SAEs (HGRSAEs) are defined as : 
• Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript as defined in Appendix 1
 of this 
protocol.  
• Primary graft failure requiring re -transplantation. 
HGR SAEs will be collected from the time a subject is transplanted with the OCS DCD Heart until the 
completion of the 30 -day follow -up evaluation. A HGRSAE will be followed until resolution or 
stabilization of the event.  
8.4.3.  Unanticipated Adverse Device Effect (UADE)  
The investigator will assess each serious adverse event for whether it is anticipated or unanticipated using the list specified in Section 8.4.4 below.  
An UADE means any serious adverse effect on health or safety or any life -threatening problem or 
death caused by, or associated with, a device, if that effect, problem, or death was not previously 
identified or encountered before at least once in standard c linical practice, in nature, severity, or 
degree of incidence in the investigational plan or application (including a supplementary plan or 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 29 of 46 application), or any other unanticipated serious problem associated with a device that relates to the 
rights, safety, or welfare of subjects.  
8.4.4.  Anticipated SAEs  
Anticipated SAEs that are associated with heart  transplant procedures within the first 30 days after 
heart  transplant  includes, but is not limited to : 
• Acute rejection  
• Atrial and ventricular arrhythmias  
• Bleeding (m ajor)  
• Hemodynamic instability  
• Death  
• Fever 
• Infection  
• Primary Graft Dysfunction  
• Respiratory failure  
• Graft failure  
• Sepsis 
• Renal dysfunction  
• Hyperammonaemia  
• Malignancy (post-transplant 
lymphoproliferative disorder (PTLD)  
• Multiple organ failure  
• Myocardial infarction  
• Neurological dysfunction  
• Hepatic dysfunction  
• Diabetes due to steroid and anti-rejection medications  
• Gall stones  
• GI bleeding  
• Pancreatitis  
• Peptic ulceration 
• Gastritis  
• Gastro esophageal reflux disease (GERD)  • Pneumo -mediastinum  
• Pneumothorax 
• Hemothorax  
• Pleural bleeding  
• Pleural effusion 
• Venous thromboembolism (deep venous thrombosis [DVT])  
• Pulmonary embolism (PE)  
• Sternal wound dehiscence  
• Organ deemed not transplantable after 
retrieval 
• Stroke  
• Psychosis  
• Cerebrovascular accid ent 
• Peripheral vascular clotting or occlusion due 
insertion of mechanical support  
• Limb gangrene due to vascular occlusion due insertion of mechanical support  
• Use of mechanical circulatory support  
• Coagulopathy  
• Hyperacute rejection  
• Anastomotic site complications; narrowing, 
bleeding or occlusion  
• Delayed sternal wound closure due to 
compromised cardiac function or excessive 
bleeding or both  
• Bowel thromboembolic complications and 
gangrene  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 30 of 46 • Aspiration  
• Cardiac tamponade  • Protamine and other anti -heparin medication 
reaction  
• Heparin ind uced thrombocytopenia  
8.4.5.  Reporting of Adverse Event s 
Unanticipated adverse device effects (UADE ) should be reported to TransMedics, Inc., within 48 hours 
of the time the investigator learns of the event, but in no case later than 5 working days  after learning 
of the event. 
All SAE information will only be collected from transplant through day 30. SAEs should be entered 
into the study database as soon as possible. SAE will be followed until the investigator designates the 
event to be either resolved or its effect on the patient’s condition stabilized. Details related to treatment of the SAE will also be collected.  
8.4.6.  Relationship of an SAE or HGRSAE to OCS Heart  System  
The investigator will assess the relationship of the HGRSAE to the OCS Heart  Syste m. The relationship 
will be assessed using the following categories:  
• Definitely Related : There is a reasonable causal and temporal relationship between 
preservation with the OCS Heart  and the adverse event.  
• Possibly Related:  There is a reasonable relationship with preservation with the OCS Heart  
and the adverse event, but the causal relationship is unclear or lacking.  
• Unlikely Related:  There is a temporal relationship with preservation with the OCS Heart  
and the adverse event, but there is not a reasonable causal relationship between the OCS Heart and the event.  
• Unrelated:  There is no relationship between preservation with the OCS Heart  and the 
adverse event.  
8.4.7.  Severity  
The investigator will rate the severity of the serious adverse event using the following categories:  
• Mild: The adverse event is transient and/or easily tolerated by the subject.  
• Moderate:  The adverse event causes the subject discomfort and interrupts the subject's 
usual activities.  
• Severe:  The adverse event causes considerable interference with the subject's usual 
activities.  
8.4.8.  Pre-Existing Conditions  
Pre-existing diseases or conditions will no t be reported as adverse events.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 31 of 46 9. OCS HEART TRAINING R UNS  
If not completed previously, prior to transplanting any DCD hearts in this study, all investigators will 
complete one or two training runs.  The purpose of these training runs is to allow the investigator and 
the surgical team to become familiar with the procurement of DCD hearts, specifically, the warm ischemia inclusion criteria, and to obtain experience in instrumenting and resuscitating DCD hearts on the OCS Heart System.  The donor organs procured and instrumented in the training runs are not 
intended for transplantation.  The results of the training runs will not be included in any data analyses, 
including the calculation of the utilization rate.  
10. STATISTICAL METHOD S 
10.1. General  
Continuous variables will be summarized using descriptive statistics, specifically the mean, median, standard deviation, minimum, and maximum. Categorical variables will be summarized using frequencies and percentages.  
10.2. Analysis Populations  
10.2.1.  DCD Heart Transplanted Recipient Population 
The DCD Heart Transplanted Recipient Population will consist of all eligible recipients who are 
transplanted with an eligible DCD donor heart that met the warm ischemic time limit defined above , 
preserved on OCS and met the transplantability criteria. The analyses of all effectiveness and safety endpoints, except the utilization rate, will be based on the DCD Heart Transplanted Recipient 
Population . 
10.2.2.  OCS Heart Population 
The OCS Heart Population will consist of all eligible donor hearts that met the warm ischemic time 
limit above and were instrumented on the OCS Heart System. The analysis of utilization  rate will be 
based on the OCS Heart population.  
10.2.3.  Modified Intend- to-Treat (mITT) Population  
The modified intend-to- treat (mITT) population will consist of all recipients who are transplanted 
according to this protocol.  The mITT analysis will be considered secondary analyses of all 
effectiveness and safety endpoints.  
10.3. Statistical Analysis  
10.3.1.  Primary Endpoint  
The primary endpoint is the patient survival at 6 months  post -transplant. 
The primary endpoint will be summarized using counts and percentages and an exact 95% confidence interval for the true percentage based on the binomial distribution.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 32 of 46 10.3.2.  Secondary and Other Endpoints   
Secondary Endpoint:  
Utilization Rate, defined  in Section  5.2. 
The rate of donor hearts that were successfully transplanted after preservation and assessment on 
the OCS Heart System (i.e., donor heart utilization) will be summarized using counts and per centages 
and an exact 95% confidence interval for the true percentage based on the binomial distribution.  
Other Endpoints : 
• Patient and graft survival at 30 days post-transplant  
• Patient and graft survival at 30 days post-transplant or at initial hospital discharge, if later 
than 30 days  
• Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined i n Appendix 1
) 
• Use of post -transplant mechanical circulatory support (LVAD, RVAD, BiVAD) for >  72 hours  
immediately post -transplant . 
• Patient survival at 1 year after transplant  
Each endpoint will be summarized using counts and percentages and an exact (Clopper -Pearson) 95% 
confidence interval for the true percentage based on the binomial distribution.  
10.4. Safety  
Serious Adverse Events (SAEs) and Heart  Graft -related Serious Adverse Events (HGRSAEs) will be 
collected within the first 30 days post- transplant and the mean number of HGRSAEs per subject will 
be summarized using descriptive statistics.  HGRSAEs are defined as  the following adverse events (at 
most one per type) : Moderate or Severe heart PGD (left or right ventricle) (not including rejection or 
cardiac tamponade) according to ISHLT consensus manuscript (as defined in Appendix 1 ) and primary 
graft failure requiring retransplantation . 
This endpoint will be summarized using descriptive statistics, specifically the mean, median, standard deviation, minimum, maximum, and a 95% confiden ce interval of the mean based on the t-
distribution. 
SAEs and HGR SAEs will also be tabulated using counts and percentages  alone and  in regards to the 
relationship of the HGR SAE to the device, and the severity of the HGR SAE.  
10.5. Sample Size Determination  
This is a continued access protocol and the sample size was not determined using statistical methods.  
11. RISK ANALYSIS  
This clinical trial has been designed to ensure that the benefits and knowledge gained from the trial 
outweigh the potential risks to the subjects.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 33 of 46 11.1. Potential Risks  
The potential risks to subjects from participation in this clinical trial include the following:  
• Potential Risks Associated with Heart  Transplant Procedures : These risks include post-
operative complications  not associated with the OCS Heart System such as graft failure, 
primary graft dysfunction, rejection, infection and other organs/systems complications, 
graft vessel disease (an expression of chronic rejection), abnormal kidney function, diabetes, high lev el of cholesterol, high blood pressure, cancer and neurological 
complications.  
• The Potential Risks Associated with OCS Heart System:  Subjects have the risk of not 
receiving organs preserved with the OCS Heart System under certain conditions including: 
(1) the OCS Heart System may not work properly, or there may not be personnel available 
trained in the use of the Heart System or (2) the OCS Heart System may malfunction, or the medical staff may make an error which could lead to damage of the donor heart. If this occurs, the subject will have to wait for a new donor heart to become available. As with any medical device, there is always a  risk of extremely rare or previously unknown side 
effects developing from the treatment.  
• Potential Risk of Using a Donor Heart  that is Unsuitable for Transplantation:  Regardless 
of the preservation system that is used, there is the risk that a patient can receive a heart  
that does not adequately function.  This trial is designed to utilize hearts that would not be 
accepted for transplantation using cold storage preservation.  There is the possibility that 
using such hearts  may  increase the risk of transplanting a heart  that that does not function 
appropriately.  It is also possible that the donor heart may not meet transplantability 
criteria af ter OCS preservation and would be turned down for transplant.  In the EXPAND 
trial and in trials of DCD donors conducted outside the U.S., only 20% of the donor hearts 
were turned down following OCS preservation so the anticipated frequency of this event is low.  
11.2. Manner in Which the Potential Risks Have Been Minimized 
The Sponsor has relied upon a number of different means, including the device design, risk analysis 
and management process, preclinical testing, and the clinical protocol itself, to minimize the risks to subjects and to protect their safety and welfare.  
The OCS Heart System has undergone extensive preclinical a nd animal studies to demonstrate that 
the device performs as intended and all materials are biocompatible . Previous clinical studies, 
including the OCS Heart EXPAND  trial and studies of DCD hearts performed outside the U.S., have  not 
indicated any safety signals that would preclude initiation of this study . 
In addition, this  clinical protocol incorporates several procedures to minimize the risks to subjects and 
to ensure the benefits of the clinical trial outweigh its potential ri sks. 
• The donor heart  acceptance criteria after OCS Heart  perfusion and assessment are  based 
on clinically relevant markers for perfusion of donor hearts on OCS and  clinical standards 
of accepting conventional donor hearts for transplantation. Thus, the donor heart  will be 
fully assessed based on the current standards of evaluating donor hearts before accepted 
for transplantation.  The recipient should not be subjected to any surgical or medical 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 34 of 46 procedures until the heart  has been accepted for transplantation by the transplanting 
team. 
• As with any heart transplant procedure, subjects will be monitored before, during and 
after the operative procedure.  The investigators have extensive experience with heart  
transplants and will be trained to use the OCS  Heart  System to further minimize risk.  
• The trial will be monitored to ensure the identification, documentation, and analysis of 
adverse events; and to ensure compliance with the protocol and procedures that are in 
place for conducting research to protect the safety  and well-being of all subjects.  
11.3. Potential Benefits  
The low utilization of donor hearts has led to a severe shortage of donor hearts to meet the large and 
growing need for heart  transplantation; the Scientific Registry for Transplant Recipients (SRTR) and 
Organ Procurement Transp lant Network (OPTN) report that approximately 25% of the patients on the 
national waiting list have either died or the ir health  deteriorated prior to a heart transplant 
procedure. 
The OCS Heart  System’s preservation and assessment c apabilities could potentially increase the rate 
of utilization of donor hearts that are not used due to the limitations of cold storage techniques.  The 
previous Heart EXPAND study demonstrated an 80% utilization of extended criteria donor hearts , and 
studi es of the OCS performed outside the U .S. observed 78 - 80% utilization of DCD hearts . This could 
improve the chances of waiting list recipients to receive a lifesaving  heart  transplant and reduce 
waiting list time and mortality.  In addition, the OCS H eart System ’s ability to assess donor hearts after 
removal allows for the assessment  of the function of the donor heart before it is transplanted.  
11.4. Risks Benefit Ratio  
Based on the above, the benefits of using OCS Heart  technology to recruit, preserve and asses s donor 
hearts to ensure their suitability for heart  transplantation outweigh the potential risks to trial 
subjects. 
12. DEVICE/SITE MANAGEMENT  
12.1. Packaging and Labeling  
The OCS Heart Perfusion Set and accessories and the Perfusion Solution will be supplied steri le and 
are intended and labeled for single use  only . 
The OCS  and its components will be clearly labeled as an investigational device according to 21 CFR 
812.5. The labeling provides instructions for use for the device.  A copy of the Instructions for Use wi ll 
be provided to each investigational site.  
12.2. Storage  
The investigational devices will be stored in a secure location . Access should be strictly limited to the 
investigators and their designees.  Neither the investigators nor any designees may provide the 
investigational device to any subject not participating in this trial. The OCS Heart  Perfusion Set should 
be stored at temperatures between - 20°C and 50°C, and ambient humidity from 10 -95%, no 
condensing. 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 35 of 46 Note: The OCS Heart  Perfusion Set should be operated at ambient temperatures (10°C to 35°C), and 
ambient humidity (20% -90%).  
12.3. Accountability  
The investigator or designee will maintain a record of investigational devices received, used, 
discarded, or returned to the Sponsor . 
12.4. Device Complaints and Malfunctions  
The investigator will inform the Sponsor of any complaints or malfunctions during the course of the 
trial. The Sponsor will investigate all device complaints and malfunctions.  
13. REGULATORY/ETHICS 
This clinical trial will be conducted in accordance with the requirements of the FDA Investigational 
Device Exemptions regulation (21 CFR Part 8 12), ISO Standard 14155,  and in accordance with good 
clinical practices.  
13.1. Institutional Review Boards (IRB)  
Prior to initiation of any trial procedures, trial documents will be submitted to each site’s IRB for 
review and approval.  In addition, any amendments to the protocol or informed consent form will be 
reviewed and approved (if necessary) by the IRB.  The Sponsor  must receive a letter documenting the 
IRB’s approval at the clinical site prior to the initiation of the trial at that particular site.  
13.2. Informed Consent 
The IRB approved written informed consent form will be signed and dated by the subject and the 
individual obtaining the consent.  The subject will be given a copy of the signed informed consent 
form.  The original will be kept in the patient’s file by the investigator.  
A copy of the proposed draft Informed Consent template is included in  Appendix 3 . 
14. DATA COLLECTION/RECO RDS/REPORTS  
14.1. Investigator Records  
Prior to participation in the investigation, the investigators will provide the following documentation 
to the Sponsor:  
• Signed Investigator Agreement   
• Signed financial disclosure f orm 
• Curriculum Vitae (CV ). 
Written approval of the protocol and informed consent document from the IRB; I nvestigators will be 
responsible to maintain on file the following records  (Note that this is not the complete list of items 
to be maintained) : 
• All relevant correspondences and required reports that pertain to the trial  
• Records of receipt, use or disposition of the investigational device  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 36 of 46 • Records of each subject’s case history and exposure to the device  
• Signed and dated consent forms  
• Relevant observations, including records concerning adverse events, condition of each 
subject upon entering and results of diagnostic tests  
• Protocol, and any amendments  
• Subject recruiting materials  
• Investigator curricula vitae.  
The investigator will not dispose of any records relevant to this trial without: (1) written permission 
from the Sponsor and (2) providing an opportunity for the Sponsor to collect such records.  The 
investigator will take responsibility for maintaining adequate and accurate electronic or hard copy source documents of all observations and data generated during this trial. Such documentation is 
subject to inspection by the Sponsor and regulatory authorities.  
14.2. Investigator Reports  
In accordance with the FDA r eporting requirements, the i nvestigators will be  required to prepare and 
submit to the Sponsor the following complete, accurate, and timely reports on this investigation when necessary:  
• The investigator will notify the Sponsor of a subject death occurring during the investigation as soon as possible, preferably within 24 hours of learning of the subject’s death, but in no event later than 48 hours.  The investigator will also notify the Sponsor 
immediately of a serious adverse event, preferably within 48 hours of learning of the serious adverse event, but in no event later than 5 working days.  
• The investigator will notify the Sponsor of any unanticipated adverse device effects (UADE) preferably within 48 hours after the investigator first learns of the effect, but in no event later than 5 working days.  The investigator will notify its IRB of any unanticipated 
adverse device effects as soon as possible, but no later than 10 working days after the 
investigator first learns of the effect.  
• The investigator will notify the Sponsor of the withdrawal of IRB approv al as soon as 
possible, but no later than 5 working days after the investigator  first learns of the 
withdrawal 
• The investigator will provide current progress reports to the Sponsor and reviewing IRB at 
regular intervals but at least on an annual basis.  
• The investigator will notify the Sponsor and the IRB of any deviation from the 
investigational plan to protect the life and physical well -being of a subject in an emergency 
as soon as possible, but no later than 5 working days after the emergency occurred.  
• The investigator will notify the Sponsor and IRB that an informed consent was not 
obtained from a subject as soon as possible, but no later than 5 working days after such an occurrence.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 37 of 46 • The investigator will provide a final summary report within 3 months after termination or 
completion of the trial to the IRB. The site trial completion report may serve as the trial 
completion for the Sponsor . 
• The investigator will provide any other information upon the request of the IRB, or the Sponsor.  
14.3. Data Collection  
All d ata required by the trial protocol will be entered into the trial database by the investigator or his 
or her designate.  A copy of draft eCRFs is provided i n Appendix 4
. 
14.4. Source Documents  
Original documentation supporting the data recorded on the CRFs must be maintained, and may 
include clinical charts, medical records, laboratory reports, physician referral or consultation letters, 
x-ray reports,  etc. Adverse events which are managed at a health care facility other than the study 
site must be reported on the case report form and every attempt must be made to obtain source documentation from that facility.  
During monitoring visits, source documents will be reviewed to ensure accuracy and validity of data recorded on the CRFs.  Source document verification will be performed by TransMedics or its  
designee, with due regard to subject confidentiality.  
14.5.  Archiving of Records  
Essential trial documents must be maintained by the Investigator for at least 2 years after the last 
marketing approval by a regulatory body, as determined by the Sponsor. The documents should be retained for a longer period, however, if required by the applicable regulatory requirements.  Records 
will be kept in a secure, dry loc ation controlled by the institution. 
15. CLINICAL MONITORING 
15.1. Monitoring  
The trial will be monitored by TransMedics. All monitors will be qualified by education, training, and experience.  After the study has been initiated, TransMedics or its designee will perform periodic 
monitoring visits to assess study progress, perform device accountability, assess the adequacy of records, and to ensure adherence to the study protocol.  Monitoring visits could be done live or via 
webconference. 
A summary of the monitoring visit, including documentation of completed previous action items 
and/or new or outstanding action items, and/or significant findings will be provided to the 
Investigator.  
In addition to periodic monitoring visits, TransMedics may perform remote monitoring  to ensure data 
are submitted in a timely manner.  Ongoing communication with investigators and study staff will be 
performed through written correspondence and telephone conversations.  
Details related to site monitoring will be documented in the Sponsor’s study- specific monitoring plan.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 38 of 46 If the investigator is not complying with the signed Investigator Agreement, the protocol, or any 
condition of the trial, (e.g., incomplete data forms) the Sponsor has the right to terminate the investigator’s participation in the trial. The Sponsor’s general monitoring procedures for 
investigational studies are described below.  
15.2. Site Initiation Visit  
TransMedics or its designee will be responsible for determining and documenting that each investigator clearly understands and accepts the responsibilities and obligations incurred in conducting a clinical study.  The sponsor or its designee will ensure, prior to study initiation, that the 
investigator:  
• Understands the requirements for device accountability   
• Understands the requirements of the clinical protocol   
• Understands reporting obligations   
• Understands and accepts the obligations to obtain informed consent  
• Understands and accepts the obligation to obtain Institutional Review Board approval of 
the protocol and informed consent form prior to the enrollment of the first subject.   
• Has adequate facilities to conduct the investigation. 
Site initiation could be done via webconference.  
15.3. Periodic Monitoring Visits  
Monitoring visits will be conducted as scheduled by the sponsor.  The monitor should visit (or conduct 
the visit via webconference) with each site as needed to ensure the following:  
• Facilities continue to be adequate and acceptable.  
• Informed consent has been obtained.  
• The protocol is being properly followed.  
• The IRB has approved or been notified of any protocol changes.  
• Accurate, complete and current records are being maintained, and the information recorded and submitted to the Sponsor is representative of the subject’s record and other supporting documentation.  
• Accurate , complete and timely adverse event reports are being submitted to the Sponsor.  
• The reason for a subject’s withdrawal from the trial has been documented.  
• Reports are being submitted to the IRB and Sponsor.  
• The appropriate staff is carrying out trial activities.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 39 of 46 15.4. Frequency of Monitoring Visits  
The frequency of monitoring visits will be determined on the basis of several factors, including the 
duration of the trial, number of subjects enrolled, number of investigators/sites, complexity of the trial, and number  of outstanding issues from previous visits.  
15.5. Study Close -out Visit  
The study close -out visit may be combined with a monitoring visit.  The following tasks will be 
completed at close -out visit. 
• Ensure that all required CRFs have been completed/submitted. 
• Ensure final disposition of investigational devices . 
• Remind the investigator of the obligation to retain the records in accordance with local country requirements, and prepare a final report for the sponsor and Institutional Review 
Board.  
15.6. Protocol Deviations  
The study should be conducted as described in this protocol.  All deviations from the protocol should 
be reported to the Sponsor by entering a protocol deviation form into the study database . 
For sites who demonstrate repeated deviations that may affect the  safety of subjects, and/or the 
integrity of the data, corrective measures will be instituted such as re -training. Continued protocol 
deviations may result in the site’s termination from the trial.  
15.7. Clinical Events Committee (CEC)  
The Sponsor will utilize an independent Clinical Events Committee (CEC)  to provide individual serious 
adverse event adjudication for the trial. It is anticipated that the CEC will meet with the Sponsor on a 
periodic basis, or as needed, depending on the rate of patient accrual.  The CEC will be guided by the 
CEC Charter;  however, t he primary responsibilities of the CEC are to:  
• Review reportable serious adverse events, including PGD, that occur over the course of 
the trial and the subsequent classification of these adverse events as related to the device . 
• Provide recommendations to extend the length of follow- up past 30 days post-transplant 
for a subject experiencing a serious adverse event.  
15.8. Data Safety Monitoring Board  & Stopping Rules  
An independent Data Safety Monitoring Board (DSMB) will be established by the Sponsor to periodically assess the progress of the trial, the safety data and the primary efficacy and safety endpoints. The DSMB will make recommendations to the Sponsor regarding continuation, 
modification or termination  of the clinical trial. The DSMB will review all data submitted to them by 
the Sponsor and may request additional information to assist in their decision process.  They will 
attend scheduled meetings and issue written minutes of their meetings; furthermore, the appointed 
Chair will be responsible for issuing final written recommendations.  
The following stopping rule is to be used in the study:  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 41 of 46 after the emergency occurred.  Protocol  amendments will be submitted to the chairman of the IRB 
responsible for reviewing amendments.  Except for “administrative letters,” investigators will await 
IRB approval of pro tocol amendments before implementing the change(s).  
18. REFERENCES  
1. Ardehali, et al. Ex -vivo perfusion of donor hearts for human transplantation (PROCEED II): a 
prospective, open- label, multicenter, randomised non -inferiority trial. Lancet . 2015 Jun 
27;385(9987):2577- 84.  
2. Chew, et al. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. 
Journal of the American College of Cardiology ; Vol 73, No.12, 2019.  
3. Dhital, et al. Adult heart transplantation with distant procurement and ex -vivo preservation of 
donor hearts after circulatory death: a case series. The Lancet , 2015, 385(9987), 2585- 2591.  
4. Dhital, et al. Rapid Retrieval and Ex -Situ Portable Ma chine Perfusion allows Successful Cardiac 
Transplantation with Donor Hearts from Controlled Donation after Circulatory Death. J. Heart Lung Transplant ; 2017.  
5. García Saéz, et al., Ex vivo heart perfusion after cardiocirculatory death; a porcine model.  J. 
Surg. Res., 2015 May 1; 95(1):311- 314, doi: 10.1016/j.jss.2014.12.039. Epub 2014 Dec 23.  
6. García Saéz, et al. Heart Transplantation after donor circulatory death in patients bridged to 
transplant with implantable left ventricular assist devices.  J. Heart  Lung Transplant. ; 2016, 
35(10): 1255- 1260.  
7. García Saéz, et al. Donor Circulatory Death Heart Transplantation with Adverse Donor and 
Recipient Risk Profile. J. Heart Lung Transplant. ; 2017, 36(45): S16. 
8. Hunt, SA, Haddad F. The changing face of heart transplantation. J. Am. Coll. Cardiol. ; 2008; 
52:587 -598.  
9. Israni, et al. OPTN & SRTR Annual Data Report 2014. American Journal of Transplantation; Volume 16, Issue S2, pages 195- 215, 11 JAN 2016 DOI: 10.1111/ajt.13673.  
10. Iyer, et al., Normothermic Ex Vivo Perfusion provides superior organ preservation and enables 
viability of hearts from DCD donors. Am J. Transplant. , 2015, 15:371- 380.  
11. Katz, et al. Advanced Therapies for End -Stage Heart Failure. Current Cardiology Reviews; 2015, 
11:63- 72. 
12. Kirklin, et al. Eighth Annual INTERMACS Report: Special focus on framing the Impact of Adverse Events. J. Heart Lung Transplant. ; 2017, 36: 1080- 1086.  
13. Kobashigawa, et al. Report from a Consensu s Conference on Primary Graft Dysfunction after 
Cardiac Transplantation. J. Heart Lung Transplant. ; 2014; 33: 327- 340.  
14. Kobashigawa, et al. Report from the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantat ion in the United States. Am J. 
Transplantation; 2017; 17:2559 -2566.  
15. Koerner, M. et al. Normothermic Ex Vivo Allograft Blood Perfusion in Clinical Heart Transplantation. Heart Surgery Forum. 2014. 17(3): E144 -145.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 42 of 46 16. Mancini, D. and Lietz, K. Selection of Cardiac Transplantation Candidates in 2010. Circulation ; 
2010; 122:173- 183. 
17. Messer, et al. Outcome after Heart Transplantation from Donation after Circulatory -
determined Death Donors. J. Heart. Lung Transplant ; 2017, 36(12):1311 -1312.  
18. Nicoara, et al. Primary Graft Dysfunction after Heart Transplantation: Incidence, Trends and 
Associated Risk Factors. Am. J. Transplant. ; 2018; 18:1461- 1470.  
19. Peura, et al. on behalf of the American Heart Association Heart Failure and Transplantation 
Committee, Recommendations for the Use of Mechanical Circulatory Support: Device 
Strategies and Patient Selection: A Scientific Statement from the American Heart Association. Circulation; 2012; 126:2648- 2667.  
20. Squiers, et al. Application of the International Society for Heart and Lung T ransplantation 
(ISHLT) criteria for Primary Graft Dysfunction after Cardiac Transplantation: Outcomes from a 
High -Volume Centre. Euro. J. Cardio -Thoracic Surg; 2017, 51:263- 270.  
21. Wilhelm, M.J. Long term outcome following heart transplantation: Current Perspective. J. 
Thoracic Dis.;  2015; 7(3):549- 551.  
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 43 of 46 APPENDIX 1:  ISHLT CONSENSUS MANUSCRIPT HEART PRIMARY GRAFT 
DYSFUNCTION (PGD) (K OBASHIGAWA, ET AL., 2014) 
 
 
 
Note : All incidences of PGD will be adjudicated by the CEC.  
Hemodynamic data will be used in the assessment of PGD severity only if collected  by centers as 
clinically indicated, per the institution’s standard of care. This approach is consistent with 
contemporary U.S. publications on PGD using ISHLT criteria (Nicoara, et al., 2018; Squiers, et al., 
2018). If hemodynamic data are not collected, the CEC will use available clinical data to adjudicate 
PGD severity grading.  
 

TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 45 of 46 APPENDIX 3:  DRAFT PATIENT INFORMED CONSENT FORM TEMPLATE  
 
(This Page is Intentionally Left Clear) 
TransMedics Confidential   OCS DCD Heart  CAP Revision 1 .0 
 
Page 46 of 46 APPENDIX 4:  DRAFT ELECTRONIC CASE REPORT FORMS 
 
(This Page is Intentionally Left Clear)  
 